Cedric Francois Sells 6,007 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,007 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72. Following the sale, the chief executive officer now owns 301,408 shares in the company, valued at $9,030,183.68. This represents a 1.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Cedric Francois also recently made the following trade(s):

• On Wednesday, January 22nd, Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total transaction of $412,356.93.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $30.76 on Friday. The company has a 50 day moving average price of $31.95 and a 200-day moving average price of $33.25. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $71.90. The stock has a market capitalization of $3.83 billion, a PE ratio of -15.15 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. During the same period in the previous year, the company posted ($1.17) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% on a year-over-year basis. Equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of APLS. Wolverine Asset Management LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. True Wealth Design LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. Capital Performance Advisors LLP purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at approximately $56,000. KBC Group NV lifted its position in Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after acquiring an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Piper Sandler cut their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Scotiabank cut their price target on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th. Evercore ISI upgraded shares of Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).